
We are looking for an experienced and talented Business Account Executive (BAE) to commercially represent GIVLAARI® and OXLUMO® in the United States and have a significant impact on the lives of AHP patients. AHP’s represent a sub-group of Porphyrias, characterized by the occurrence of neuro-visceral attacks with or without cutaneous manifestations. AHP’s include four disorders: acute intermittent porphyria (the most common), variegate porphyria, hereditary coproporphyria, and a genetic deficit of delta-aminolaevulinic acid dehydratase. PH1 is a rare, life-threatening disease that can cause serious damage to kidneys and progressively to other organs. PH1 is a little-known condition and patients often spend years undiagnosed and misdiagnosed.
The BAE will be principally responsible for driving physician and patient identification, disease awareness, overall market development, and brand awareness within their ascribed territory. The BAE will be responsible for achieving territory targets and other business objectives through account and customer strategies, while also partnering & collaborating very closely with internal and external stakeholders to effectively manage all aspects of the regional business. The achievement of targets will be based in Alnylam’s values: our commitment to people, sense of urgency, passion for excellence, innovation & discovery, and open culture as well as our unwavering commitment to integrity.
The BAE will report to the Regional Business Director (RBD) for their respective region.
Geographic Territory: This role is responsible for covering Northern California, including the San Francisco Bay Area and Sacramento, as well as Southern Oregon, including Medford and Klamath Falls.
Must live in the assigned territory.
#LI-SS1 #LI-Remote

SILENCE DISEASE. AMPLIFY LIFE.™
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.
Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases.
We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024).
We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America.
See our social media community guidelines: https://bit.ly/2FcRhJy.
Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861
Fraudulent Recruitment Activity
Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."